Regulation of two-pore-domain (K 2P) potassium leak channels by the tyrosine kinase inhibitor genistein

British Journal of Pharmacology

Volumn 154, Issue 8, 2008, Pages 1680-1690

  Gierten, J ^a   Ficker, E ^b   Bloehs, R ^a   Schlomer K ^a   Kathofer S ^a   Scholz, E ^a   Zitron, E ^a   Kiesecker, C ^a   Bauer, A ^a   Becker, R ^a   Katus, H A ^a   Karle, C A ^a   Thomas, D ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Background potassium current; Cardiac arrhythmia; Cardioprotection; Cellular excitability; Ischaemic preconditioning; K2P channel; Leak channel; Membrane potential; Protein phosphorylation; Tyrosine kinase

Indexed keywords

COMPLEMENTARY DNA; GENISTEIN; GENISTIN; ORTHOVANADIC ACID; POTASSIUM CHANNEL; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; TWO PORE DOMAIN POTASSIUM CHANNEL;

ANIMAL CELL; ARTICLE; BINDING SITE; CHO CELL; CONTROLLED STUDY; DEPOLARIZATION; DRUG MECHANISM; HUMAN; IC 50; ION TRANSPORT; MEMBRANE POTENTIAL; MOLECULAR MECHANICS; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PATCH CLAMP; POTASSIUM CURRENT; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN DOMAIN; REPOLARIZATION; VOLTAGE CLAMP; XENOPUS;

ANIMALS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; ELECTROPHYSIOLOGY; GENISTEIN; HUMANS; INHIBITORY CONCENTRATION 50; NERVE TISSUE PROTEINS; OOCYTES; PATCH-CLAMP TECHNIQUES; PHOSPHORYLATION; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; XENOPUS LAEVIS;

EID: 49449100453     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.213     Document Type: Article

References (57)

1. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N et al. (1987). Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592-5595.
2. Akiyama T, Ogawara H (1991). Use and specificity of genistein as inhibitor of protein-tyrosine kinases. Methods Enzymol 201: 362-370.
3. Alexander SPH, Mathie A, Peters JA (2007). Guide to receptors and channels. Br J Pharmacol 150 (Suppl 1): S1-S168.
4. Altomare C, Tognati A, Bescond J, Ferroni A, Baruscotti M (2006). Direct inhibition of the pacemaker (If) current in rabbit sinoatrial node cells by genistein. Br J Pharmacol 147: 36-44.
5. + channel TASK-1 contributes to arrhythmogenic effects of platelet-activating factor. Am J Physiol 282: H2024-H2030.
6. + channels. Mol Interv 4: 205-219.
7. 2+ channel activity by a tyrosine kinase-independent mechanism. Mol Pharmacol 62: 554-565.
8. 2+/calmodulin-dependent protein kinase II and epidermal growth factor receptor. Mol Cell Biochem 268: 175-183.
9. + channel, TASK-1, inducing repolarization abnormalities in cardiac ventricular myocytes. J Biol Chem 279: 33154-33160.
10. + channel TREK-1. EMBO J 24: 44-53.
11. + channel by Gq protein α-subunits. Proc Natl Acad Sci USA 103: 3422-3427.
12. Cho CH, Song W, Leitzell K, Teo E, Meleth AD, Quick MW et al. (2005). Rapid upregulation of α7 nicotinic acetylcholine receptors by tyrosine dephosphorylation. J Neurosci 25: 3712-3723.
13. SO, by zinc. J Physiol 560: 51-62.
14. Cohen A, Zilberberg N (2006). Fluctuations in Xenopus oocytes protein phosphorylation levels during two-electrode voltage clamp measurements. J Neurosci Methods 153: 62-70.
15. Dixon RA, Ferreira D (2002). Genistein. Phytochemistry 60: 205-211.
16. Fatehi-Hassanabad Z, Parratt JR (1997). Genistein, an inhibitor of tyrosine kinase, prevents the antiarrhythmic effects of preconditioning. Eur J Pharmacol 338: 67-70.
17. + channels? Cell 130: 563-569.
18. Fryer RM, Schultz JE, Hsu AK, Gross GJ (1998). Pretreatment with tyrosine kinase inhibitors partially attenuates ischemic preconditioning in rat hearts. Am J Physiol 275: H2009-H2015.
19. Gescher AJ, Sharma RA, Steward WP (2001). Cancer chemoprotection by dietary constituents: a tale of failure and promise. Lancet Oncol 2: 371-379.
20. Goldstein SAN, Bayliss DA, Kim D, Lesage F, Plant LD, Rajan S (2005). International Union of Pharmacology. LV. Nomenclature and molecular relationships of two-P potassium channels. Pharmacol Rev 57: 527-540.
21. Goldstein SAN, Bockenhauer D, O'Kelly I, Zilberberg N (2001). Potassium leak channels and the KCNK family two-P-domain subunits. Nat Rev Neurosci 2: 175-184.
22. Haendeler J, Berk BC (2000). Angiotensin II mediated signal transduction. Important role of tyrosine kinases. Regul Pept 95: 1-7.
23. Han J, Truell J, Gnatenco C, Kim D (2002). Characterization of four types of background potassium channels in rat cerebellar granule neurons. J Physiol 542: 431-444.
24. + channel involved in neuroprotection and general anesthesia. EMBO J 23: 2684-2695.
25. Hool LC, Middleton LM, Harvey RD (1998). Genistein increases the sensitivity of cardiac ion channels to β-adrenergic receptor stimulation. Circ Res 83: 33-42.
26. Imagawa J, Baxter GF, Yellon DM (1997). Genistein, a tyrosine kinase inhibitor, blocks the 'second window of protection' 48 h after ischemic preconditioning in the rabbit. J Mol Cell Cardiol 29: 1885-1893.
27. + channels TREK-2 and TRAAK. J Physiol 564: 103-116.
28. 2 in the control of neuronal excitability? J Cell Mol Med 8: 38-44.
29. Kiehn J, Thomas D, Karle CA, Schöls W, Kübler W (1999). Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol 359: 212-219.
30. Lakshman M, Xu L, Ananthanarayanan V, Cooper J, Takimoto CH, Helenowski I et al. (2008). Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res 68: 2024-2032.
31. Lalevee N, Monier B, Senatore S, Perrin L, Semeriva M (2006). Control of cardiac rhythmby ORK1, a Drosophila two-pore domain potassium channel. Curr Biol 16: 1502-1508.
32. + channels. J Biol Chem 278: 32068-32076.
33. Lopes CMB, Gallagher PG, Buck ME, Butler MH, Goldstein SAN (2000). Proton block and voltage-gating are potassium-dependent in the cardiac leak channel Kcnk3. J Biol Chem 275: 16969-16978.
34. Lopes CMB, Zilberberg N, Goldstein SAN (2001). Block of Kcnk3 by protons: evidence that 2-P-domain potassium channel subunits function as homodimers. J Biol Chem 276: 24449-24452.
35. Lu Z, Gao J, Zuckerman J, Mathias RT, Gaudette G, Krukenkamp I et al. (2007). Two-pore K(+) channels, NO and metabolic inhibition. Biochem Biophys Res Commun 363: 194-196.
36. Marban E (2002). Cardiac channelopathies. Nature 415: 213-218.
37. Mathie A (2007). Neuronal two pore domain potassium channels and their regulation by G protein coupled receptors. J Physiol 578: 377-385.
38. Millar JA, Barratt L, Southan AP, Page KM, Fyffe REW, Robertson B et al. (2000). A functional role for the two-pore domain potassium channel TASK-1 in cerebellar granule neurons. Proc Natl Acad Sci USA 97: 3614-3618.
39. + current in guinea-pig ventricular myocytes. J Physiol 573: 469-482.
40. O'Dell TJ, Kandel ER, Grant SG (1991). Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors. Nature 353: 558-560.
41. + channels in rabbit portal vein smooth muscle. Br J Pharmacol 122: 1395-1404.
42. Paillart C, Carlier E, Guedin D, Dargent B, Couraud F (1997). Direct block of voltage-sensitive sodium channels by genistein, a tyrosine kinase inhibitor. J Pharmacol Exp Ther 280: 521-526.
43. Park D, Huang T, Frishman WH (2005). Phytoestrogens as cardioprotective agents. Cardiol Rev 13: 13-17.
44. + channels. Trends Neurosci 24: 339-346.
45. + channels. Curr Opin Cell Biol 13: 422-427.
46. + channel. EMBO J 17: 4283-4290.
47. Putzke C, Wemhöner K, Sachse FB, Rinne S, Schlichthörl G, Li XT et al. (2007). The acid-sensitive potassium channel TASK-1 in rat cardiac muscle. Cardiovasc Res 75: 59-68.
48. Rajan S, Plant LD, Rabin ML, Butler MH, Goldstein SAN (2005). Sumoylation silences the plasma membrane leak channel K2P1. Cell 121: 37-47.
49. Richter TA, Dvoryanchikov GA, Chaudhari N, Roper SD (2004). Acid-sensitive two-pore domain (K2P) channels in mouse taste buds. J Neurophysiol 92: 1928-1936.
50. Sarker FH, Li Y (2006). Using chemoprotective agents to enhance the efficacy of cancer therapy. Cancer Res 66: 3347-3350.
51. 2+ channel activity in human atrial myocytes. J Mol Cell Cardiol 37: 735-745.
52. Thomas D, Wendt-Nordahl G, Röckl K, Ficker E, Brown AM, Kiehn J (2001). High affinity blockade of HERG human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. J Pharmacol Exp Ther 297: 735-761.
53. Thomas D, Zhang W, Karle CA, Kathöfer S, Schöls W, Kübler W et al. (1999). Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A. J Biol Chem 274: 27457-27462.
54. Veale EL, Kennard LE, Sutton GL, MacKenzie G, Sandu C, Mathie A (2007). Gαq-mediated regulation of TASK3 two-pore domain potassium channels: The role of protein kinase C. Mol Pharmacol 71: 1666-1675.
55. Wischmeyer E, Döring F, Karschin A (1998). Acute suppression of inwardly rectifying Kir2.1 channels by direct tyrosine kinase phosphorylation. J Biol Chem 273: 34063-34068.
56. Yu HG, Lu Z, Pan Z, Cohen IS (2004). Tyrosine kinase inhibition differentially regulates heterologously expressed HCN channels. Pflugers Arch 447: 392-400.
57. -channel blockers on depolarization-activated potassium currents in rat ventricular myocytes. Exp Physiol 92: 549-559.